Literature DB >> 12220775

Intrapartum antibiotic prophylaxis 2: positive predictive value of antenatal group B streptococci cultures and antibiotic susceptibility of clinical isolates.

Rodney K Edwards1, Penny Clark, Patrick Duff.   

Abstract

OBJECTIVE: To estimate the probability of positive intrapartum group B streptococcus cultures among women previously identified as carriers of this organism, and to estimate the susceptibility of group B streptococci to six commonly used antibiotics.
METHODS: We performed a prospective cohort study of women identified as carriers of group B streptococci by current pregnancy genital tract (group 1) or urine cultures (group 2), or a positive culture in a prior pregnancy (group 3). Intrapartum culture specimens were obtained, and isolates were tested for susceptibility to six antibiotics using the agar disk diffusion technique.
RESULTS: Intrapartum cultures were positive for 68% (62, 73), 61% (49, 72), and 48% (36, 60) of groups 1 (n = 249), 2 (n = 69), and 3 (n = 59), respectively. Cultures were positive in 67% (61, 73) of women in group 1 whose cultures were done 42 days or less before delivery (n = 218). The proportion of isolates (n = 239) susceptible to penicillin, ampicillin, cefazolin, and vancomycin was 100% (98, 100). The proportion susceptible to clindamycin and erythromycin was 91% (87, 94) and 79% (73, 84), respectively.
CONCLUSION: The positive predictive value of antenatal group B streptococci cultures is lower than was previously reported. Clindamycin and erythromycin are not optimal agents for prophylaxis against early-onset neonatal group B streptococcal infection in patients who are allergic to penicillin.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12220775     DOI: 10.1016/s0029-7844(02)02097-5

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  8 in total

Review 1.  Molecular-based screening for perinatal group B streptococcal infection: implications for prevention and therapy.

Authors:  Stéphane Emonet; Jacques Schrenzel; Begoña Martinez de Tejada
Journal:  Mol Diagn Ther       Date:  2013-12       Impact factor: 4.074

2.  Intrapartum group B Streptococcus screening in the labor ward by Xpert® GBS real-time PCR.

Authors:  C Plainvert; F El Alaoui; A Tazi; C Joubrel; O Anselem; M Ballon; A Frigo; C Branger; L Mandelbrot; F Goffinet; C Poyart
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-10-29       Impact factor: 3.267

3.  Assessment of intrapartum antibiotic prophylaxis for the prevention of early-onset group B Streptococcal disease.

Authors:  Feng-Ying C Lin; Leonard E Weisman; Parvin Azimi; Amy E Young; Kathleen Chang; Mikhaela Cielo; Patricia Moyer; James F Troendle; Rachel Schneerson; John B Robbins
Journal:  Pediatr Infect Dis J       Date:  2011-09       Impact factor: 2.129

Review 4.  Group B Streptococcus vaccine development: present status and future considerations, with emphasis on perspectives for low and middle income countries.

Authors:  Miwako Kobayashi; Johan Vekemans; Carol J Baker; Adam J Ratner; Kirsty Le Doare; Stephanie J Schrag
Journal:  F1000Res       Date:  2016-09-22

5.  Patterns of antibiotic resistance among group B streptococcus isolates: 2001-2004.

Authors:  Lubna Chohan; Lisa M Hollier; Karen Bishop; Charles C Kilpatrick
Journal:  Infect Dis Obstet Gynecol       Date:  2006

6.  Cost-effectiveness of universal prophylaxis in pregnancy with prior group B streptococci colonization.

Authors:  Mark A Turrentine; Mildred M Ramirez; Joan M Mastrobattista
Journal:  Infect Dis Obstet Gynecol       Date:  2009-12-13

7.  Maternal group B streptococcal (GBS) genital tract colonization at term in women who have asymptomatic GBS bacteriuria.

Authors:  David S McKenna; Scott Matson; Ike Northern
Journal:  Infect Dis Obstet Gynecol       Date:  2003

Review 8.  Antibiotic use and misuse during pregnancy and delivery: benefits and risks.

Authors:  Begoña Martinez de Tejada
Journal:  Int J Environ Res Public Health       Date:  2014-08-07       Impact factor: 3.390

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.